The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACAD | +52.07% | -48.99% | -12.58% | +224% |
| S&P | +16.23% | +94.45% | +14.22% | +501% |
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
An analyst upgrade is sparking a rally in the drugmaker's shares today.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $264.57M | 9.3% |
| Gross Profit | $243.83M | 9.0% |
| Gross Margin | 92.16% | -0.3% |
| Market Cap | $3.61B | 34.5% |
| Market Cap / Employee | $5.52M | 0.0% |
| Employees | 654 | 9.4% |
| Net Income | $26.67M | -20.1% |
| EBITDA | $35.31M | 7.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $253.64M | 43.2% |
| Accounts Receivable | $107.51M | 3.7% |
| Inventory | 26.1 | -63.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.60M | -5.5% |
| Short Term Debt | $11.69M | 11.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 20.77% | 16.8% |
| Return On Invested Capital | -20.25% | 12.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $63.66M | 154.5% |
| Operating Free Cash Flow | $63.96M | 155.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 19.91 | 13.49 | 12.09 | 16.21 | -82.20% |
| Price to Book | 4.43 | 5.29 | 3.78 | 4.71 | -18.45% |
| Price to Sales | 2.75 | 3.19 | 2.80 | 3.57 | 17.77% |
| Price to Tangible Book Value | 5.42 | 6.47 | 4.52 | 5.56 | -26.59% |
| Price to Free Cash Flow TTM | 12.61 | 19.46 | 18.76 | 19.45 | -42.04% |
| Enterprise Value to EBITDA | 59.62 | 192.99 | 97.09 | 83.06 | 21.47% |
| Free Cash Flow Yield | 7.9% | 5.1% | 5.3% | 5.1% | 72.53% |
| Return on Equity | 27.4% | 38.9% | 37.2% | 33.2% | 395.29% |
| Total Debt | $49.37M | $52.00M | $56.01M | $56.29M | -2.36% |
ACAD earnings call for the period ending November 8, 2021.
ACAD earnings call for the period ending June 30, 2021.
ACAD earnings call for the period ending March 31, 2020.
ACAD earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
